PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 6th, 2025 • Pineapple Financial Inc. • Finance services • New York
This letter (the “Agreement”) constitutes the agreement between D. Boral Capital LLC (the “Placement Agent”) and Pineapple Financial Inc., a company organized under the law of Canada (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a reasonable “best efforts” basis, in connection with the proposed offering (the “Placement”) of (i) common shares (the “Shares”) of the Company (the “Common Shares”), no par value per share (the “Common Stock”), (ii) warrants to purchase Common Shares (the “Common Warrants”), and (iii) pre-funded warrants to purchase Common Shares (the “Pre-Funded Warrants” and, together with the Shares and Common Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Securities.” The Shares, the Pre-Funded Warrants, the Common Warrants, and the Common Shares underlying the Pre-Funded Warrants and Common Warrants will be offered and sold under the C
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 1st, 2025 • Pineapple Financial Inc. • Finance services • New York
This letter (the “Agreement”) constitutes the agreement between D. Boral Capital LLC (the “Placement Agent”) and Pineapple Financial Inc., a company organized under the law of Canada (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a reasonable “best efforts” basis, in connection with the proposed offering (the “Placement”) of (i) common shares (the “Shares”) of the Company (the “Common Shares”), no par value per share (the “Common Stock”), (ii) warrants to purchase Common Shares (the “Common Warrants”), and (iii) pre-funded warrants to purchase Common Shares (the “Pre-Funded Warrants” and, together with the Shares and Common Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Securities.” The Shares, the Pre-Funded Warrants, the Common Warrants, and the Common Shares underlying the Pre-Funded Warrants and Common Warrants will be offered and sold under the C
Placement Agency AgreementPlacement Agency Agreement • March 28th, 2025 • Tenon Medical, Inc. • Surgical & medical instruments & apparatus • New York
Placement Agency AgreementPlacement Agency Agreement • March 27th, 2025 • Tenon Medical, Inc. • Surgical & medical instruments & apparatus • New York
Placement Agency AgreementPlacement Agency Agreement • March 10th, 2025 • Incannex Healthcare Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 28th, 2025 • PDS Biotechnology Corp • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a reasonable “best efforts” basis, in connection with the proposed offering (the “Placement”) of (i) shares (the “Shares”) of common stock of the Company, par value $0.00033 per share (the “Common Stock”), (ii) warrants to purchase shares of Common Stock (the “Common Warrants”), and (iii) pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants” and, together with the Shares and Common Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Securities.” The Shares, the Pre-Funded Warrants, the Common Warrants and the shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants will be offered and so
Placement Agency AgreementPlacement Agency Agreement • January 30th, 2025 • Processa Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • January 27th, 2025 • Processa Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • January 16th, 2025 • Processa Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 20th, 2024 • Professional Diversity Network, Inc. • Services-computer programming, data processing, etc. • New York
Placement Agency AgreementPlacement Agency Agreement • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • October 31st, 2024 • Palladyne AI Corp. • Services-prepackaged software • New York
Placement Agency AgreementPlacement Agency Agreement • September 23rd, 2024 • Fortress Biotech, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • September 17th, 2024 • Tenon Medical, Inc. • Surgical & medical instruments & apparatus • New York
Placement Agency AgreementPlacement Agency Agreement • September 9th, 2024 • Tenon Medical, Inc. • Surgical & medical instruments & apparatus • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 27th, 2024 • ShiftPixy, Inc. • Services-employment agencies • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 20th, 2024 • ShiftPixy, Inc. • Services-employment agencies • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • July 30th, 2024 • ShiftPixy, Inc. • Services-employment agencies • New York
Placement Agency AgreementPlacement Agency Agreement • May 17th, 2024 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • May 13th, 2024 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Placement Agency AgreementPlacement Agency Agreement • April 18th, 2024 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 26th, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Aspira Women’s Health Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a reasonable “best efforts” basis, in connection with the proposed offering (the “Placement”) of (i) shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), warrants to purchase share of Common Stock (the “Common Warrants”) and (iii) pre-funded warrants to purchase Shares (the “Pre-Funded Warrants” and together with the Shares and Common Warrants, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Securities.” The Shares, Pre-Funded Warrants, and the shares of Common Stock underlying the Pre-Funded Warrants will be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-2